The Global Medical Device Contract Manufacturing Market Will Reach $90.5bn In 2020 Predicts New Visiongain Report

06 September 2018
Pharma

A new report by visiongain predicts that the Global Medical Device Contract Manufacturing market will reach $90.5bn in 2020. This forecast and others appear in Medical Device Contract Manufacturing Market Forecast 2016-2026: Prospects for Electronic Manufacturing Services, Materials Processing and Finished Products published in May 2016. Visiongain is a business information provider based in London, UK.

This report examines the current and future trends in the growing medical device contract manufacturing market. We expect the ageing population to be a major driver over the forecast period. As the ageing population increases so will the incidence of chronic diseases in developing economies. The opportunities for original equipment manufacturers (OEMs) to develop more technologically advanced medical devices to treat chronic diseases will lead to an increase in outsourcing components to contract manufacturers. The multidisciplinary knowledge and expertise held by contract manufacturing organizations (CMOs) will become more attractive to OEMs over the forecast period as OEMs seek to equip their products with the latest and most innovative technology for patient healthcare.
In this report, we examine in detail the medical device contract manufacturing market, and provide analyses and forecasts for regional and national markets. We also look into the major drivers and restraints and how these will help shape the medical device contract manufacturing market in the next ten years. Historical revenues, where available, have also been added to strengthen our analysis of how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety and more.

Yemi Adebayo, a Pharmaceutical and Medical Devices Industry Analyst at visiongain, said: “The medical device contract manufacturing market is expected to see fast growth over the next ten years. Contract manufacturers will be dearly sought for design and manufacturing purposes as technology continues to develop. Major advances in technology provide opportunities for innovation in improving patient healthcare. Ekso Bionics, for example, a leading developer of exoskeleton technologies has been able to develop a robotic exoskeleton — Ekso GT™ that is able to be used on patients with hemiplegia due to stroke and patients with spinal cord injury. In terms of diabetes treatment, Tandem Diabetes Care, a company focused on providing insulin infusion therapies has been able to develop an insulin pump (t:slim® Insulin Pump) that is able to hold a large capacity of insulin whilst at the same time retain an attractive, modern touch-screen design and allow ease of use to patients. Although in previous years OEMs feared outsourcing at the prospect of losing product quality. CMOs today have improved their alignment with regulatory requirements and continue to provide ample opportunities for OEMs internationally. These are just some of the factors that will lead to the large growth in the medical device contract manufacturing market in the coming years.”
Visiongain’s report provides revenue forecasts to 2026 for the global medical device market, the global medical device outsourcing market, the global medical device contract manufacturing market, regional medical device contract manufacturing markets and leading national markets. The report discusses selected leading companies in the market. These companies include Flextronics, Jabil Circuit, Benchmark Electronics, Greatbatch, The Tech Group (West Pharmaceutical Services), Tecomet (Symmetry Medical), Nortech Systems, TE Connectivity (Creganna Medical), Forefront Medical Technology, Vention Medical

Medical Device Contract Manufacturing Market Forecast 2016-2026: Prospects for Electronic Manufacturing Services, Materials Processing and Finished Products adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 61
About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever